Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Predictive Analytics Help Identify Drug Candidate Molecules

Posted on January 26th, 2019 by

Pharma R&D

predictive analytics new

The process of discovering a viable drug candidate molecule is often time-consuming and research-intensive. A lab must test thousands of compounds every day — and a hit rate of just 1 percent is considered above average. Continue reading “Predictive Analytics Help Identify Drug Candidate Molecules” »

Government Shutdown Could Have Lasting Impact on Scientific Research

Posted on January 26th, 2019 by

Pharma R&D

govt shutdown new

The U.S. government shutdown dragged on past the one-month mark, creating financial panic for many government workers and resulting in a ripple of negative affects across the country. Continue reading “Government Shutdown Could Have Lasting Impact on Scientific Research” »

Pharma Industry Associations Air Their Concerns Following Rejection of Brexit Deal

Posted on January 23rd, 2019 by

Pharma R&D

brexit new

There has always been a special relationship between the United States and the United Kingdom that gives the two nations a unique connection. Unfortunately, lately, the two have also shared quite a bit of upheaval and uncertainty in their respective governments. Continue reading “Pharma Industry Associations Air Their Concerns Following Rejection of Brexit Deal” »

Growth, recognition, results—and an important partnership

Posted on January 17th, 2019 by

Pharma R&D

sigilon new

Here at Sigilon Therapeutics, we have had a very exciting period of growth recently, including receiving an Advanced Therapy Medicinal Product (ATMP) designation from the European Medicines Agency, adding two new members to our leadership team and initiating a collaboration with Eli Lilly in type 1 diabetes. Continue reading “Growth, recognition, results—and an important partnership” »

Government Shutdown Means New Drugs May Have to Wait – But Safety Monitoring Will Continue

Posted on January 17th, 2019 by

Pharma R&D

biopharma new

The partial shutdown of the U.S. government, which began just before the Christmas holiday, has been especially terrible for hundreds of thousands of federal employees who are either furloughed or working without pay. Continue reading “Government Shutdown Means New Drugs May Have to Wait – But Safety Monitoring Will Continue” »

Avoiding Pitfalls and Costly Mistakes in Early Stage R&D

Posted on January 17th, 2019 by

Pharma R&D

tufts new

Pharma R&D costs continue to rise rapidly. A well-known Tufts study estimated the average pre-tax cost per new approved prescription drug (including failures and capital costs) was nearly $2.6 billion in 2013. However, the creation of novel approved drugs has not kept up with investment over the past two decades. Continue reading “Avoiding Pitfalls and Costly Mistakes in Early Stage R&D” »

  1. 1
  2. 2
  3. 3
  4. …
  5. 61


About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.